Safety and immunogenicity of pneumococcal conjugate vaccines in preterm infants

References

• Black RE, Cousens S, Johnson HL, et al. Mothers for the child health epidemiology reference group of WHO and UNICEF. 2010. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet. 2010;375:1969–1987.
   PubMed Web of Science ®Google Scholar
• Rückinger S, van der Linden M, von Kries R. Effect of heptavalent pneumococcal conjugate vaccination on invasive pneumococcal disease in preterm born infants. BMC Infect Dis. 2010;10:12.
   PubMed Web of Science ®Google Scholar
• Hjuler T, Wohlfahrt J, Simonsen J, et al. Perinatal and crowding-related risk factors for invasive pneumococcal disease in infants and young children: a population-based case-control study. Clin Infect Dis. 2007;44(8):1051–1056.
   PubMed Web of Science ®Google Scholar
• Lee LH, Gu XX, Nahm MH. Towards new broader spectrum pneumococcal vaccines: the future of pneumococcal disease prevention. Vaccines (Basel). 2014 Feb 14;2(1):112–128.
   PubMedGoogle Scholar
• Simonsen L, Taylor RJ, Schuck-Paim C, et al. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. Lancet Respir Med. 2014 May;2(5):387–394.
   PubMed Web of Science ®Google Scholar
• Simonsen L, Taylor RJ, Young-Xu Y, et al. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. mBio. 2011;2(1):e00309–e00310.
   PubMed Web of Science ®Google Scholar
• Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 2010 Oct 5;7(10):pii: e1000348.
   PubMed Web of Science ®Google Scholar
• Gladstone RA, Jefferies JM, Faust SN, et al. Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults. Expert Rev Vaccines. 2012 Aug;11(8):889–902.
   PubMed Web of Science ®Google Scholar
• McIntosh ED, Reinert RR. Global prevailing and emerging pediatric pneumococcal serotypes. Expert Rev Vaccines. 2011 Jan;10(1):109–129.
   PubMed Web of Science ®Google Scholar
• Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 2010 Mar;14(3):e197–e209.
   PubMed Web of Science ®Google Scholar
• Mrkvan T, Pelton SI, Ruiz-Guiñazú J, et al. Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: review of clinical trials and post-marketing experience. Expert Rev Vaccines. 2018 Sep;17(9):797–818.
   PubMed Web of Science ®Google Scholar
• Plosker GL. 13-valent pneumococcal conjugate vaccine: a review of its use in infants, children, and adolescents. Paediatr Drugs. 2013 Oct;15(5):403–423.
   PubMed Web of Science ®Google Scholar
• Gagneur A, Pinquier D, Quach C. Immunization of preterm infants. Hum Vaccin Immunother. 2015;11(11):2556–2563.
   PubMed Web of Science ®Google Scholar
• Shinefield H, Black S, Ray P, et al. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Pediatr Infect Dis J. 2002 Mar;21(3):182–186.
   PubMed Web of Science ®Google Scholar
• De Waure C, Specchia ML, Capizzi S, et al. Effectiveness of 7-valent pneumococcal conjugate vaccine: A meta-analysis of post-marketing studies. World J Metaanal. 2015 Jun 26;3(3):151–162.
   Web of Science ®Google Scholar
• Esposito S, Pugni L, Bosis S, et al. Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants. Vaccine. 2005 Feb 25;23(14):1703–1708.
   PubMed Web of Science ®Google Scholar
• Ruggeberg JU, Collins C, Clarke P, et al. Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants. Vaccine. 2007 Jan 4;25(2):264–271. Epub 2006 Aug 4.
   PubMed Web of Science ®Google Scholar
• Moss SJ, Fenton AC, Toomey JA, et al. Responses to a conjugate pneumococcal vaccine in preterm infants immunized at 2, 3, and 4 months of age. Clin Vaccine Immunol. 2010 Nov;17(11):1810–1816.
   PubMed Web of Science ®Google Scholar
• D’Angio CT, Heyne RJ, O’Shea TM, et al. Heptavalent pneumococcal conjugate vaccine immunogenicity in very-low-birth-weight, premature infants. Pediatr Infect Dis J. 2010 Jul;29(7):600–606.
   PubMed Web of Science ®Google Scholar
• Szynczewska E, Chlebna-Sokół D. Immunogenicity of heptavalent conjugate vaccine against Streptococcus pneumoniae in premature babies with low birth weight. Pediatr Neonatol. 2014 Apr;55(2):101–107.
   PubMed Web of Science ®Google Scholar
• Omeñaca F, Merino JM, Tejedor JC, et al. Immunization of preterm infants with 10-valent pneumococcal conjugate vaccine. Pediatrics. 2011 Aug;128(2):e290–e298.
   PubMed Web of Science ®Google Scholar
• Martinón-Torres F, Czajka H, Center KJ, et al. 13-valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infants. Pediatrics. 2015 Apr;135(4):e876–e886.
   PubMed Web of Science ®Google Scholar
• Martinón-Torres F, Wysocki J, Center KJ, et al. Circulating antibody 1 and 2 years after vaccination with the 13-valent pneumococcal conjugate vaccine in preterm compared with term infants. Pediatr Infect Dis J. 2017 Mar;36(3):326–332.
   PubMed Web of Science ®Google Scholar
• Kent A, Ladhani SN, Andrews NJ, et al. Schedules for pneumococcal vaccination of preterm infants: an RCT. Pediatrics. 2016;138(3):e20153945.
   PubMed Web of Science ®Google Scholar
• Ben Jmaa W, Hernández AI, Sutherland MR, et al. Cardio-respiratory events and inflammatory response after primary immunization in preterm infants < 32 weeks gestational age: a randomized controlled study. Pediatr Infect Dis J. 2017 Oct;36(10):988–994.
   PubMed Web of Science ®Google Scholar
• Wilińska M, Warakomska M, Głuszczak-Idziakowska E, et al. Risk factors for adverse events after vaccinations performed during the initial hospitalization of infants born prematurely. Dev Period Med. 2016;20(4):296–305.
   PubMedGoogle Scholar
• Silfverdal SA, Coremans V, François N, et al. Safety profile of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Expert Rev Vaccines. 2017 Feb;16(2):109–121.
   PubMed Web of Science ®Google Scholar
• Duan K, Guo J, Lei P. Safety and immunogenicity of pneumococcal conjugate vaccine in preterm infants: a meta-analysis. Indian J Pediatr. 2017 Feb;84(2):101–110.
   PubMed Web of Science ®Google Scholar